AstraZeneca Assigns Four More Brands to Edelman
Charting the future of public relations
Holmes Report
CEO

AstraZeneca Assigns Four More Brands to Edelman

AstraZeneca, one of the world’s largest research-based pharmaceutical companies, has retained Edelman to develop and orchestrate U.S. communications programs for four key brands.

Paul Holmes

NEW YORK—AstraZeneca, one of the world’s largest research-based pharmaceutical companies, has retained Edelman to develop and orchestrate U.S. communications programs for four key brands: Seroquel Tablets, an antipsychotic for the treatment of schizophrenia; Toprol-XL, a beta blocker for hypertension, angina and heart failure; Atacand, an angiotension receptor blocker for hypertension; and the company’s investigational anticoagulant Exanta, which is expected to be the first direct oral thrombin inhibitor to reach the market in more than fifty years.  

These recent wins significantly expand Edelman’s partnership with Astrra-Zeneca, which began four years ago when the company named Edelman agency of record for the investigational cholesterol treatment, Crestor. Edelman now represents the AstraZeneca cardiovascular franchise in the U.S., and its work with the company encompasses multiple public relations, public affairs, and medical education assignments across the U.S., Europe and Asia. 

Says  Steve Lampert, executive director for public affairs at AstraZeneca, “Edelman demonstrated a perfect balance between strategy and creative energy, which made them our clear choice.”

View Style:

Load 3 More
comments powered by Disqus